Biofil Chemicals & Pharmaceuticals Q2 Results 2026: PAT ₹0 Cr +50%
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹2Cr
- −87.7% YoY
- −86.5% QoQ
- Net profit
- ₹0Cr
- +50% YoY
- +9.1% QoQ
- Margin
- 6%
- +5.2 pp YoY
- +4.9 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs.
As stated in Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.
Based on Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.
From Biofil Chemicals & Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Biofil Chemicals & Pharmaceuticals' revenue grow in the September 2026 quarter?
- Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs.
- Corresponding Quarter Previous Year (Q2 30/09/2025): ₹1,214.47 Lakhs (Pharma Unit), ₹139.61 Lakhs (Chemicals Division); Total Gross Turnover ₹1,354.08 Lakhs.
- Year-on-Year Revenue Change for Pharma Unit: Decrease from ₹1,214.47 Lakhs (prev. year quarter) to ₹166.87 Lakhs (current quarter).
2 more points from Biofil Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
What happened to Biofil Chemicals & Pharmaceuticals' margins in Q2 FY27?
Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.
Locked: what Biofil Chemicals & Pharmaceuticals Ltd said on margins
Also locked on this page: fundraising
Free account, 30 seconds. No card needed.
What capex is Biofil Chemicals & Pharmaceuticals planning?
- The company is undertaking renovation and upgradation of its manufacturing facility pursuant to the revision in Schedule M of the Drugs and Cosmetics Rules.
- The upgradation work is expected to be completed within approximately 3 to 6 months from the date of the report (November 14, 2026).
- The enhanced manufacturing capabilities, upon completion, are expected to improve sales in subsequent periods.
- Capital expenditure in property, plant, and equipment during the half year ended 30.09.2026 was ₹9.20 Lakhs.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Biofil Chemicals & Pharmaceuticals raising money or cutting debt?
The cash flow statement on page 8 shows cash flow from financing activities with a net decrease in…
Locked: what Biofil Chemicals & Pharmaceuticals Ltd said on fundraising
Also locked on this page: margins
Free account, 30 seconds. No card needed.
How big is Biofil Chemicals & Pharmaceuticals' order book?
- Financial data provided focus on segment revenue, profit, capital employed, assets, liabilities, cash flow, and earnings.
- No operational metrics related to order bookings or order inflows are included.
Biofil Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2 | 14 | -87.7% | 12 | -86.5% |
| Operating profit (EBITDA) | 0 | 0 | -9.1% | 0 | -28.6% |
| Operating margin | 6% | 0.8% | +5.2 pp | 1.1% | +4.9 pp |
| Profit before tax | 0 | 0 | +36.4% | 0 | +15.4% |
| Net profit (PAT) | 0 | 0 | +50% | 0 | +9.1% |
| EPS (₹) | 0.07 | 0.05 | +40% | 0.07 | 0% |
Source: Biofil Chemicals & Pharmaceuticals Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aarey Drugs (Q2 FY27)
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Biofil Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Biofil Chemicals & Pharmaceuticals Ltd Q2 FY27 results?
Quarterly Revenue (Q2 ended 30/09/2026): ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Quarterly EBITDA: Rs. 56 Crores, up 54% YoY.
What is Biofil Chemicals & Pharmaceuticals Ltd share price analysis?
Biofil Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 107.7 with a market cap of ₹52 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biofil Chemicals & Pharmaceuticals Ltd planning capital expenditure?
The company is undertaking renovation and upgradation of its manufacturing facility pursuant to the revision in Schedule M of the Drugs and Cosmetics Rules.
Keep Biofil Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
